Evidence map›Paper›PMID 39624798›Full record

ArticleMolecular therapy. Methods & clinical development2024

Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.

Winnie L Liu, Eleftheria Kampouri, John K Bui, Mandeep K Sekhon, Almudena Tercero, Dan Finlay, Liya H Asghedom, Gladys R Romasanta, Natalie T Rice, Fatima Ranjbaran and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Winnie L LiuFred Hutchinson Cancer Center, Seattle, WA, USA.
Eleftheria KampouriFred Hutchinson Cancer Center, Seattle, WA, USA.
John K BuiFred Hutchinson Cancer Center, Seattle, WA, USA.
Mandeep K SekhonFred Hutchinson Cancer Center, Seattle, WA, USA.
Almudena TerceroDeverra Therapeutics, Seattle, WA, USA.
Dan FinlayFred Hutchinson Cancer Center, Seattle, WA, USA.
Liya H AsghedomFred Hutchinson Cancer Center, Seattle, WA, USA.
Gladys R RomasantaDeverra Therapeutics, Seattle, WA, USA.
Natalie T RiceFred Hutchinson Cancer Center, Seattle, WA, USA.
Fatima RanjbaranFred Hutchinson Cancer Center, Seattle, WA, USA.
Carrie StoltzmanDeverra Therapeutics, Seattle, WA, USA.
Jody CookDeverra Therapeutics, Seattle, WA, USA.
Joe BlakeDeverra Therapeutics, Seattle, WA, USA.
Colleen S DelaneyDeverra Therapeutics, Seattle, WA, USA.
Joshua A HillFred Hutchinson Cancer Center, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low levels and function of natural killer (NK) cells are associated with increased coronavirus disease 2019 (COVID-19) severity. NK cell immunotherapy may improve immune function to reduce infection severity. We conducted a first-in-human, open-label, phase 1, dose-escalating (100 × 10

Indexed as

allogeneiccellular therapyCOVID-19immunotherapynatural killer cell therapyNK cellSARS-CoV-2T cell therapy

Identifiers

PMID39624798
PMCPMC11609367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.